Drugs / Attenuvax
Trials 2 · a red edge is where a trial was stopped
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 21 trial | ||||||
| Phase 2 | NCT00000815 | ? → Aug 2001 | HIV infectious disease, measles | National Institute of Allergy and Infectious Diseases (NIAID) | Completed | No outcome recorded |
| Phase 31 trial | ||||||
| Phase 3 | NCT04429295 | Jun 2020 → Feb 2021 | Rotavirus infection, diphtheria, haemophilus meningitis, hepatitis B virus infection +3 | Sanofi Pasteur, a Sanofi Company | Completed | No outcome recorded |
Evidence & citations 4 cited values
Every value below carries the sentence it was read from. 3 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | Attenuvax | ClinicalTrials.gov intervention name — accepted as the source's own label NCT00000815 ↗ |
| Known as | Human Rotavirus, live attenuated | ClinicalTrials.gov intervention name — accepted as the source's own label NCT04429295 ↗ |
| Modality | Vaccine | “monovalent measles vaccine (Attenuvax)” PMID 21666159 ↗ Jul 2011 |
| Route | Subcutaneous | “administered subcutaneously” NCT00000815 ↗ |